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Abstract
Background: Tuberculosis is a leading cause of death in people living with HIV (PLWH). We conducted a meta analysis to
assess the effect of tuberculosis on mortality in people living with HIV.
Methods: Meta-analysis of cohort studies assessing the effect of tuberculosis on mortality in PLWH. To identify eligible
studies we systematically searched electronic databases (until December 2008), performed manual searches of citations
from relevant articles, and reviewed conference proceedings. Multivariate hazard ratios (HR) of mortality in PLWH with and
without tuberculosis, estimated in individual cohort studies, were pooled using random effect weighting according to ‘‘Der
Simonian Laird method’’ if the p-value of the heterogeneity test was ,0.05.
Results: Fifteen cohort studies were systematically retrieved. Pooled overall analysis of these 15 studies estimating the effect
of tuberculosis on mortality in PLWH showed a Hazard Ratio (HR) of 1.8 (95% confidence interval (CI): 1.4–2.3). Subanalysis of
8 studies in which the cohort was not exposed to highly active antiretroviral therapy (HAART) showed an HR of 2.6 (95% CI:
1.8–3.6). Subanalysis of 6 studies showed that tuberculosis did not show an effect on mortality in PLWH exposed to HAART:
HR 1.1 (95% CI: 0.9–1.3).
Conclusion: These results provide an indication of the magnitude of benefit to an individual that could have been expected
if tuberculosis had been prevented. It emphasizes the need for additional studies assessing the effect of preventing
tuberculosis or early diagnosis and treatment of tuberculosis in PLWH on reducing mortality. Furthermore, the results of the
subgroup analyses in cohorts largely exposed to HAART provide additional support to WHO’s revised guidelines, which
include promoting the initiation of HAART for PLWH co-infected with tuberculosis. The causal effect of tuberculosis on
mortality in PLWH exposed to HAART needs to be further evaluated once the results of more cohort studies become
available.
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Introduction
People living with HIV (PLWH) are estimated to have a 20
times higher risk on developing tuberculosis (TB) disease
compared to people living without human immunodeficiency
virus (HIV) infection in countries with an HIV prevalence of at
least 1%.[1] Fifteen percent of the incident TB cases in 2008 are
estimated to be co-infected with human immunodeficiency virus
(HIV).[1] TB is the leading direct cause of death among PLWH in
Africa and a major cause of death elsewhere.[2,3] The estimated
number of incident TB cases in PLWH was 1.4 million in 2008
(range 1.3–1.5 million). An estimated 0.52 million (range 0.45–
0.62 million) TB deaths occurred in 2008 among PLWH (38%,
range 31%–45%).[1] Africa accounted for 79% of the HIV-
positive TB cases, followed by South-East Asia with 13%.[1]
In PLWH, HIV infection increases the risk of progressing from
TB infection to TB disease.[4] Furthermore, TB may act as
cofactor in the progression of HIV infection by increasing the HIV
viral load through inducing a faster HIV replication and/or by
contributing to a reduction in the CD4 cell count.[5] The
widespread use, since 1996, of highly active antiretroviral therapy
(HAART) has substantially improved the prognosis of HIV-
infected patients both in industrialised and low-income settings [6]
and survival in HIV/TB co-infected individuals.[7,8]
Although there seems to be consensus that TB does accelerate
HIV replication, the impact of TB disease on HIV disease
progression at the population level is less clear.[9] According to
the International Classification of Diseases (ICD-10) deaths from
TB in PLWH are classified as HIV deaths.[3][10] Previously, a non
systematic pooled analysis showed that TB was weakly associated
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confidence interval (CI): 1.0–1.2).[11] This non-systematic pooled
analysis assessed the effect of various exposures (TB or TB as an
AIDS defining condition) on various endpoints (mortality in PLWH
or mortality in PLWH having developed AIDS during follow up
period), which may have substantially increased heterogeneity. The
aim of our meta-analysis was to assess the effect of TB on mortality
in a broad cross-section of the population of PLWH.[12]
Methods
A protocol was developed in advance of conducting this
systematic review and meta-analysis.
Search strategy and selection criteria
To identify cohort studies assessing the effect of TB on mortality
in PLWH we searched for publications in the PubMed, Embase
and Scopus databases through December 2008. The combination
of key words (exploded MESH headings and free text terms) in the
search strategy included HIV Infections, AIDS-Related Opportu-
nistic Infections, Acquired Immunodeficiency Syndrome, cohort
study, tuberculosis, mortality, survival, HIV, AIDS. Furthermore,
reference listing of eligible studies was conducted and we hand-
searched abstracts of relevant TB and AIDS conferences till 2008.
We contacted authors of eligible studies to identify additional
published and unpublished studies. Identified studies were
reviewed for eligibility by two authors (MS, MvdW) based on
title and abstract. Eligible studies were cohort studies assessing the
effect of TB on mortality in a HIV positive cohort by calculating
multivariate hazard ratios (HR) and corresponding 95% CI
through Cox Proportional Hazard models. Studies not fulfilling
the eligibility criteria, studies defining the cohort on AIDS status,
and studies not reporting a mortality rate (e.g. only included death
PLWH) were excluded. A priori we did not exclude non-English
articles but all full text articles of the potential eligible studies
appeared to be in English.
Data extraction
One reviewer (MS) extracted data from all eligible studies and a
second reviewer (MvdW) independently extracted data from a
subset of articles. Data extraction included information on study
setting, study population, cohort size, duration of follow up,
antiretroviral therapy (ART), baseline CD4 cell count, baseline
HIV viral load, exclusion of patients with TB history, mortality,
type of statistical model and measures of association estimating the
effect of TB on mortality. Authors of six included studies were
approached to provide additional information or asked for
clarification if needed.
Quality assessment
Quality assessment of eligible studies was done according to the
Newcastle-Ottawa Quality Assessment Scale for cohort studies.[13]
This scale seemed most appropriate for our purpose and does
include important quality features of cohort studies.[14,15] We did
not assess the study quality of two studies [16,17] because the full
text was unavailable at time of submission of this manuscript.
Quantitative data synthesis
Log HR of the multivariate analyses in the individual cohort
studies were combined using the inverse variance method.
Heterogeneity across studies was estimated by calculating I
2.
Random effect weighting according to the Der Simonian Laird
method [18] was conducted when the p-value of the heterogeneity
test was ,0.05. Four studies estimated the multivariate HR by
marginal structural Cox proportional hazard models and standard
Coxproportionalhazardmodels.[8,11,19,20]Forthemainanalyses
we pooled the results obtained by the standard Cox proportional
hazard model to be more consistent with the other studies that only
estimated the multivariate HR by standard Cox proportional
hazardmodel.The stratifiedanalysesoftwostudiesnot reportingan
overall estimate were included as separate studies.[21,22] Because
these stratified analyses include different individuals we are not
subject to double counting of data.[23] To prevent too much weight
of one study assessing mortality separately in HIV1 and HIV2
positives [21] we only included the stratified analyses assessing effect
of TB on mortality in HIV1 positives.
The eligible studies included TB patients who either had TB
diagnosis confirmed at study entry (‘prevalent TB patients’);
patients who did not have TB at study entry but who developed
TB during the course of the study (‘incident TB patients’) and
studies including both ‘prevalent’ and ‘incident’ TB patients.
‘Incident TB’ did not necessarily indicate a new episode of TB in a
person without prior TB, it might also indicate a recurrence of TB
as not all studies have excluded PLWH with a prior history of TB.
In the main analyses we have estimated the effect of ‘incident’,
‘prevalent’ and ‘incident’+‘prevalent’ TB on mortality. In the
secondary analyses we estimated pooled HRs in the following
subpopulations:
N Baseline CD4 cell count ,200 m/L;
N Studies conducted before the introduction of HAART (,1996)
or reporting that less than 10% of the HIV positives had
initiated HAART;
N Studies conducted in 1996 or thereafter and reporting $10%
or $50% HAART initiation by PLWH;
N Studies conducted in the USA, Africa, Asia and Europe.
Sensitivity analyses were conducted excluding studies with lower
quality according to the quality assessment tool. Publication bias
was assessed by a scatter plot (funnelplot) of the log HR (x-axis)
versus precision defined as 1/standard error (y axis) of the 15
studies included in the main analyses. Analyses were conducted
with STATA 10.
Results
Selection of included studies
We identified 15 cohort studies comparing mortality in PLWH
with and without TB that were eligible for our meta-analysis
(Figure 1). The funnel-plot (Figure 2) suggests a lack of publications
on small sized studies that did not show an effect of TB on
mortality in PLWH.
Study characteristics
Table S1 presents the study characteristics of the individual
studies. Ten [8,11,19–22,24–27] of the 15 included cohort studies
that were prospective and five were retrospective [16,17,28–30].
The majority of the studies (87%) included both HIV positive
males and females recruited from hospitals, primary care units and
research institutes[8,16,17,19,21,22,24–29,31] while 2 studies
included either only males[11] or females [20] recruited from
similar institutions.
Information on TB diagnosis could be obtained for 11 studies. In 9
studies TB was defined as sputum smear positive confirmed by
culture (definite TB) or clinical and radiologic improvement after TB
treatment (probable TB), in a patient with clinical signs and
symptoms consistent with active TB. [11,20,22,28,21,26,27,29,31]
In 2 studies TB was primarily diagnosed by sputum smear
Effect of TB on Mortality in HIV Positive People
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ities without culture confirmation. [8,16] PLWH with prior TB
diagnosis were excluded from participation in five studies
[11,20,22,28,29] while in nine studies TB history was not an
exclusion criteria [8,16,17,19,24,25,27,31,33] and one study did not
report on TB history.[26] Ten studies were conducted during or after
1996, the era coinciding with availability of HAART [8,11,16,17,19–
21,24–26] of which eight reported that part of the cohort(s) had
initiated HAART.[8,11,16,17,20,24,25,32] In four studies all PLWH
initiated HAART.[19,24–26]
Table S2 presents the individual results of studies assessing the
effect of TB on mortality in PLWH. Ten studies [11,16,20–22,26–
29,31] reported in at least one of their analyses a statistically
significantly increased hazard on mortality of $1.5 in PLWH with
TB compared to PLWH without TB (Table S2).
Meta-analysis
Main results. Including all 15 studies that estimated the
effect of TB on either all cause mortality or AIDS-related mortality
in PLWH showed a pooled HR of 1.8 (95% CI: 1.4–2.3) (Figure 3).
Excluding one study that reported on AIDS-related mortality
instead of all cause mortality [11], the estimated effect of TB on
mortality in PLWH was similar (HR: 1.8; 95% CI: 1.4–2.3)
(Table 1, Analyses 2.1). Excluding three studies in which TB was
only measured at study entry (‘prevalent TB’) [16,19,25] showed
similar results (HR: 1.9 (95% CI: 1.5–2.6) (Table 1, Analyses 2.2).
Limiting the analyses to those five HIV positive cohorts without
TB at study entry but estimating the effect of ‘incident’ TB on all
cause mortality in HIV positives, risk of mortality was 2.6 times
higher for HIV positives who developed TB compared to HIV
positives who did not develop (HR: 2.6 (95% CI: 1.6–4.1)).
(Table 1, Analyses 3.1).
Results of secondary and sensitivity analyses
CD4 cell count. Four studies either included only PLWH
with baseline CD4 cell count #200 cells/mL [19] or conducted
stratified analyses [21,26,31] to assess the effect of TB (‘prevalent’,
‘incident’, ‘prevalent+incident’) on mortality in PLWH with
baseline CD4 cell count #200 cells/mL. Across these four
Figure 1. Flow diagram of papers accepted and rejected during selection procedure.
doi:10.1371/journal.pone.0015241.g001
Figure 2. Funnelplot of 15 studies estimating the effect of
tuberculosis on either all cause mortality or AIDS-related
mortality in people living with HIV. Points indicate log hazard
ratios (x-axis) from 15 studies (contributing to 18 separate hazard
ratio’s) assessing the effect of ‘‘prevalent’’, ‘‘incident’’, and ‘‘prevalen-
t+incident’’ TB on AIDS-related/all cause mortality in HIV positive
individuals. Precision is calculated as 1/standard error. A lower precision
indicates a more accurate estimate.
doi:10.1371/journal.pone.0015241.g002
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CD4 #200 cells/mL (HR 1.5; 95% CI: 1.1–2.1) was similar to that
among PLWH including all CD4 levels (Figure 4).
HAART. TB had a large effect on mortality in PLWH
participating in a study conducted before HAART was available:
HR 2.6 (95% CI: 1.8–3.6). (Table 1, Analyses 5.1) When including
one study that was conducted during the HAART era but of
which less than 10% of the cohort had been exposed to HAART
resulted in a similar HR: 2.6 (95% CI: 1.9 to 3.5) (Figure 5). In
contrast, the subset of studies in which at least 50% of the cohort
was reported to be exposed to HAART did not show an effect of
TB on mortality: HR 1.1 (95% CI: 0.9–1.3) (Figure 6).
Geographical region. Stratifying the studies per region
showed that TB was significantly associated with an increased
hazard of mortality in PLWH in the USA and Africa and reaching
statistically significance in Europe (Table 1, Analyses 6.1–6.4). For
Asia, no increased TB-associated mortality risk was observed
based on the results of only two studies. [17,26]
The three sensitivity analyses showed that excluding studies with
relatively low scores on the quality assessment scale resulted in
similar HRs (Table 1, Analyses S1–S3).
Discussion
This meta-analysis shows that PLWH with TB face an
approximately two times higher risk of death from all causes
compared to PLWH without TB. The increased hazard of
mortality implies that PLWH with TB die earlier compared to
PLWH without TB.
Diagnosing TB in PLWH is difficult due to the more frequent
presentation with atypical symptoms and the increased proportion
of both smear-negative pulmonary TB and extra pulmonary
TB.[4,34–37] Apart from these difficulties, access to health
services and treatment in high HIV prevalence resource
constrained settings is restricted due to an increased demand on
over-stretched and under-resourced TB services [38], which may
also be geographically out of reach for a significant proportion of
the affected population.[34] These factors may result in late
diagnosis, more advanced TB, delay and/or lack of specific TB
treatment and poorer TB treatment outcomes contributing to a
pronounced mortality effect of TB in PLWH. [4,34,35,39]
The increased risk of dying in PLWH with TB disease may,
instead of dying from TB, be due to HIV-related conditions.[38,40]
The development of incident TB is indicative of a poor immune
recovery. The poor prognosis following a diagnosis of TB suggests
that TB in PLWH could be considered as a proxy for severe
immunosuppression, with associated poor survival [40] which may
be the consequence of an increased risk of dying from HIV-related
conditions.[38] In five studies assessing cause of mortality and
including PLWH initiating TB treatment, the percentage of HIV
positive TB patients dying during TB treatment from TB varied
from 16% to 46% of the total HIV positive deaths during TB
Figure 3. Studies assessing the effect of ‘‘prevalent’’, ‘‘incident’’ and ‘‘prevalent’’+‘‘incident’’ TB on AIDS-related/all cause mortality
in HIV positive individuals. Study ID on the Y-axis refers to first author and publication year; % weight refers to influence of each study on overall
estimate (weights are from random effect analyses); for each study the central diamond indicates multivariate hazard ratio, line represents 95%
confidence interval (CI), and the grey square reflects the study’s weight in the pooling; overall estimate refers to pooled estimate of hazard ratio after
mathematical combination of all studies; the X-axis indicates the scale and the direction of the effect of tuberculosis on mortality in HIV positive
individuals. I-squared denotes the extent of heterogeneity in study outcomes, with a (hypothetical) value of 100% meaning considerable
heterogeneity and 0% meaning no heterogeneity between studies.
doi:10.1371/journal.pone.0015241.g003
Effect of TB on Mortality in HIV Positive People
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15241treatment.[41–45] These results indicate that more than half of the
HIV positive TB patients, TB is not the main cause of death. Other
main causes of death included pneumonia [41,42,45], gastro
intestinal disease [44,45], wasting syndrome, Kaposi’s sarcoma
[41,44], meningitis [44], (other) opportunistic infections [41,42]
[44], toxic epidermal necrolysis [45], miscellaneous [41] or
unknown causes.[41,42,44,45]
Our meta-analysis results indicate that in cohorts of PLWH of
which at least 50% of the cohort had been exposed to HAART,
TB did not seem to have a higher risk of death compared to those
PLWH without TB (HR 1.1; 95% CI: 0.9–1.3). Several reasons
may explain why we did not find an effect of TB on mortality in
the subset of patient populations with high HAART use. We
further discuss the post hoc conclusion of our subgroup
analyses.[46] The first possibility is that the ‘true’ effect of TB
on mortality in PLWH in advanced stages of HIV infection may
have been obscured, because of their high risk of dying from other
HIV-related conditions.[42] It is also possible that PLWH who
survived early death related to TB were more likely, compared to
TB patients who died before initiating HAART, to benefit from
HAART due to increased CD4 cell count after HAART
initiation.[8,47] This may possibly result in reductions of risks
for major life threatening opportunistic infections [48] that has
been associated with lower mortality hazard.[49] For the majority
of the included studies CD4 cell count was only measured at
baseline therefore the hypothesized clinical treatment success of
HAART, as expressed in increase of CD4 cell count, could not be
determined based on our results. PLWH initiating HAART may
have been taking anti-TB therapy for weeks which might have
reduced the survival difference between PLWH with and without
TB.[24] Timing and duration of TB treatment could not be
determined for most of the studies [17,19,24–26] in which $50%
of the PLWH initiated HAART. Previously, studies have reported
a reduction in TB related mortality in PLWH initiating
HAART.[50,51] These results are in line with the results of our
meta-analysis. A retrospective cohort study on PLWH and TB of
which one group started with HAART after initiating TB
treatment reported that most observed deaths were due to non
TB related conditions.[50] Another cohort study showed that
among PLWH, TB-related mortality tended to be lower in PLWH
receiving HAART compared to PLWH without HAART.[52]
Our findings that PLWH and TB did not seem to have an higher
risk on mortality compared to those PLWHI without TB in
cohorts largely exposed to HAART can also be explained by
Table 1. Pooled multivariate hazard ratios among subgroups of studies estimating the effect of TB on all cause mortality in HIV
positive individuals.
Heterogeneity
Analyses N Studies
N separate
HRs
Pooled Hazard
Ratio (95% CI) p* I
2 References
Timing of TB diagnosis
‘‘prevalent’’, ‘‘incident’’,
‘‘prevalent+incident’’
2.1 14 17 1.8 (1.4–2.3) 0.00 82.6% [8,16,17,19,20,21,22,24,25,
26,27,28,29,31]
‘‘incident’’, ‘‘prevalent+incident’’ 2.2 11 14 1.9 (1.5–2.6) 0.00 84.6% [8,17,20,21,22,24,26,27,28,29,31]
‘‘incident’’ 3.1 5 8 2.6 (1.6–4.1) 0.00 87.7% [8,20,21,22,29]
‘‘prevalent’’ 3.2 3 3 1.5 (0.9–2.2) 0.03 72.6% [16,19,25]
‘‘prevalent + incident’’ 3.3 5 5 1.1 (1.0–1.2) 0.12 45% [8,17,24,26,27]
CD4 #200 cells/mL
4 3 6 1.5 (1.1–2.1) 0.01 70.4% [19,21,26]
Year + % report HAART
,1996 or report NO HAART 5.1 8 11 2.6 (1.8–3.6) 0.00 73% [20,21,22,26,27,28,29,31]
,1996 or #10% report HAART 5.2 9 12 2.6 (1.9–3.5) 0.00 70.7% [16,20,21,22,26,27,28,29,31]
$1996+$10% 5.3 7 7 1.1 (0.99–1.3) 0.90 0.0% [8,17,19,20,24,25,26]
$1996+$50% 5.4 6 6 1.1 (0.9–1.3) 0.75 0.0% [17,19,20,24,25,26]
Geographic region
USA 6.1 2 2 2.4 (1.3–4.3) { 0.95 0.0% [11,20]
Africa 6.2 8 11 2.2 (1.6–3.2) { 0.00 84.1% [16,19,21,22,24,25,27,31]
Asia 6.3 2 2 1.1 (0.8–1.4) 0.87 0.0% [17,26]
Europe 6.4 3 3 1.8 (0.95–3.3) 0.01 76.9% [8,28,29]
Sensitivity analyses 1
Excluding scoring 0 or 1 on
‘comparability’
S1 9 11 1.6 (1.2–2.1) 0.00 84.6% [8,19,20,21,24,25,26,27,31]
Excluding scoring 0 or 1 on ‘outcome’ S2 9 12 1.9 (1.4–2.6) 0.00 82.9% [19,20,21,22,24,25,26,29,31]
Excluding overall score ,67% S3 10 13 1.8 (1.3–2.4) 0.00 84.6% [8,19,20,21,22,24,25,26,29,31]
*The weights are from the random effect analyses if p,0.05 and the weights are from the fixed analyses if p$0.05;
{The HR indicates the effect of TB on all cause/AIDS related mortality because Lo ´pez Gattell, et al (2008)
11 reports the effect of TB on AIDS-related mortality;
{For both studies the multivariate hazard ratios as assessed by the marginal structural Cox proportional hazard have been included;
1Analyses number 2.1 formed the basis for the sensitivity analyses.
doi:10.1371/journal.pone.0015241.t001
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already died before initiating HAART. This could have resulted in
an underestimation of mortality associated with TB. However, we
do not think that such selection bias had a large impact on our
pooled estimate as in three studies PLWH still developed TB after
initiating HAART.[17,24,26] Information bias may have masked
the effect of TB on mortality in PLWH during the HAART era
due to under diagnosis or misdiagnosis of TB patients. Support for
this hypothesis is the fact that two studies reported that TB
diagnosis was only conducted at HAART initiation and compared
mortality in PLWH and TB at HAART initiation to mortality in
PLWH without TB at HAART initiation.[19,25] Individuals in
this latter group may have developed TB but this has not been
diagnosed because of the specific study design. Furthermore, one
study [24] specifically mentions that new TB infections occurring
while patients are receiving ART had not been well diagnosed in
the specific setting. In addition, misclassification of TB patients in
this specific HAART setting may have occurred since culture and
smear results from the primary healthcare clinics were lacking in
one study [19] and TB diagnosis is more difficult in the last stage
of immunodeficiency in patients who are severely malnourished
and may present with atypical symptoms.[25] A final hypothetical
explanation for an absence of TB excess mortality in HAART
cohorts is that TB may be the reason for diagnosing HIV and
consequently initiating HAART. Thus in the HAART era PLWH
may benefit from their TB because it could be a reason for starting
HAART earlier thereby stopping and or slowing their decline to
death.
Possible biases related to meta-analysis
The interpretation of the funnel plot suggested a lack of smaller
sized studies not showing an effect of TB on mortality in PLWH.
This may imply that the results of this meta-analysis are
overestimated. However, other sources of biases may have
counterbalanced this effect by underestimating the effect of TB
on mortality. By using Cox Proportional Hazard analyses the
individual HRs may well have been biased because of lack of
adjustment for time dependent confounders in the analyses.[53]
When assessing the impact of TB on mortality in PLWH, CD4 cell
count may act as time dependent confounder. Lower CD4 cell
counts are associated with increased risk of mortality
[4,31,47,49,54–56] but also with increasing incidence of TB
[57–60] while the presence of TB disease is associated with
reduced CD4 cell counts.[19] Consequently, a lower CD4 cell
count not only predicts and increases the risk of mortality but also
influences the likelihood of developing TB and can play an
intermediate role in the causal effect chain when assessing the
impact of TB on mortality. Standard survival analyses may give
biased estimates in the presence of time dependent confound-
ers.[53] All 15 studies controlled in their overall analyses for
baseline values of CD4 cell count. This may have resulted in
underestimating the effect of TB on mortality by ignoring the
effect that TB may have had on mortality through its mediation on
CD4 cell counts.[20] Marginal structural models have been
introduced to estimate the causal effect of a time-dependent
exposure in the presence of time-dependent covariates that may be
simultaneously confounders and intermediate variables.[61] In 3
out of 15 studies marginal structural models were construct-
ed[8,11,20] and TB status varied in time. The impact of TB on
mortality was higher when the marginal structural model had been
constructed compared to the HR as obtained by the Cox
Proportional Hazard Analyses. These results may provide support
to the hypothesis that the pooled effect of TB on mortality in
PLWH is an underestimated effect. Other potential time
Figure 4. Studies assessing the effect of ‘‘prevalent’’, ‘‘incident’’ and ‘‘prevalent’’+‘‘incident’’ TB on all cause mortality in HIV
positive individuals with baseline CD4 cell count #200 cells/mL. Study ID on the Y-axis refers to first author and publication year; % weight
refers to influence of each study on overall estimate (weights are from random effect analyses); for each study the central diamond indicates
multivariate hazard ratio, line represents 95% confidence interval (CI), and the grey square reflects the study’s weight in the pooling; overall estimate
refers to pooled estimate of hazard ratio after mathematical combination of all studies; the X-axis indicates the scale and the direction of the effecto f
tuberculosis on mortality in HIV positive individuals.
doi:10.1371/journal.pone.0015241.g004
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viral load or other time varying markers of immunosuppression.
Because of heterogeneity between the studies we have
conducted stratified analyses for low CD4 cell count, HAART
exposure and region. Meta-regression analyses constitute another
possibility to decrease study heterogeneity, but requires informa-
tion on the main covariates of all included studies, which was
unavailable for our meta-analysis.[46] Additionally, we faced the
limitation that we only identified 15 eligible studies which
decreased the potential for robust conclusions.
Despite the a priori defined in- and exclusion criteria, the main
analyses assessing the effect of ‘incident’, ‘prevalent’ or ‘incident +
prevalent’ TB on mortality showed substantial heterogeneity
across studies, as expressed by I
2 varying from 45% to 88%. The
studies with ‘prevalent TB patients’ [8,11,16,17,19,24–28,31] may
consist of a heterogeneous cohort of TB patients having already
completed several months of TB treatment as well as individuals
who are diagnosed at baseline. We used random effect models
when heterogeneity was large allowing studies to come from
multiple source populations with different distributions between
exposure and effect. Because all individual multivariate HRs of the
included studies in the main analyses were in similar direction we
conclude that the heterogeneity does not impact the direction of
the association as found in our meta-analysis, although the
heterogeneity may impact on ‘no effect’ versus ‘increased hazard’.
Overall, the quality of the various studies was fairly comparable
and excluding the studies with the lowest quality score did not
influence the main results. Assessing the quality of studies is
sensitive to written information provided in the published
manuscripts. Most studies did not get the highest quality score
because there was no description on the measurement of TB
mortality or a statement on the follow-up time.
Generalisability
In this meta-analysis we have included studies that selected the
cohort based on its participants having a positive HIV status.
Although PLWH receiving HAART may be in a more advanced
immunosuppressive level than those not receiving HAART, we
feel that our choice to only include studies that selected their
cohorts based on HIV positive status and not based on the
presence of AIDS has enabled us to obtain a population more
representative of the average individual infected with HIV.
Conclusions
This meta-analysis supports evidence that PLWH who develop
TB are at increased risk for mortality. Our results are based on
observational studies and do not unequivocally establish but imply
causality between TB and earlier mortality in PLWH and TB
disease.[62] If we admit a causal interpretation then our results
would provide an indication of the magnitude of benefit to an
individual that could have been expected if the episode of TB had
been prevented.[62]
The results emphasize the need for additional studies assessing
the effect of preventing TB or early diagnosis and treatment of TB
in PLWH on reducing mortality. This may be obtained by
providing isoniazid preventive therapy (IPT) which has been
associated with decreased mortality in HIV positives co-infected
Figure 5. Studies assessing the effect of ‘‘prevalent’’, ‘‘incident’’ and ‘‘prevalent’’+‘‘incident’’ TB on all cause mortality in HIV
positive individuals before HAART era (,1996) or #10% of cohort has reported use of HAART. Study ID on the Y-axis refers to first
author and publication year; % weight refers to influence of each study on overall estimate (weights are from fixed effect analyses); for each study the
central diamond indicates multivariate hazard ratio, line represents 95% confidence interval (CI), and the grey square reflects the study’s weight in the
pooling; overall estimate refers to pooled estimate of hazard ratio after mathematical combination of all studies; the X-axis indicates the scale and the
direction of the effect of tuberculosis on mortality in HIV positive individuals.
doi:10.1371/journal.pone.0015241.g005
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reduced by infection control activities to reduce the spread of TB
(especially in health facilities) and intensified case finding to pro
actively identify TB in people with HIV. [65]
The results of our subgroup analyses in cohorts largely exposed
to HAART provide additional support to WHO’s revised
guidelines which include promoting the initiation of ART for all
those with HIV/TB co-infection, irrespective of WHO disease
stage or CD4 cell count. [66] We feel that currently available data
are insufficient to draw definite conclusions about the causal effect
of TB on mortality in PLWH exposed to HAART. This should be
further evaluated once the results of additional cohort studies
become available in which exposure and adherence to HAART
has been documented. Ideally, these studies would prospectively
follow individuals starting from HIV seroconversion so that there
is information on person years for all phases of HIV infection. TB
should be assessed regularly by using standardized approaches
including laboratory testing and mortality in PLWH who do and
do not develop incident TB should be compared when. [67]
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